Navigation Links
Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy
Date:7/13/2010

New Rochelle, NY, July 13, 2010Improved delivery methods and better testing systems are needed to advance promising gene therapy strategies for treating prostate cancer, according to a series of review articles in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc (www.liebertpub.com). The articles and an accompanying editorial are available free online at www.liebertpub.com/hum

Prostate cancer is one of the most common types of cancer affecting men in the U.S. and is the second leading cause of cancer death among men, after lung cancer. Among the most recent treatment strategies being tested against prostate cancer is gene therapy, in which a gene product intended to destroy the tumor cells or to stimulate the patient's immune system to fight the cancer is delivered to the tumor, typically using a viral delivery vector. The most common approach uses an adenovirus as the delivery vector and has been shown to be quite safe.

However, it is still not clear which genes, viral vectors, or strategies are optimal to ensure targeted delivery of the genes to the tumor cells, and uptake by the tumor, to achieve the most effective, most potent, and safest treatment that can lead to a cure for prostate cancer. Stefan Kochanek, from the University of Ulm, Germany, and Bernd Gnsbacher, from the Technical University of Munich, Germany, present their views on the need for developing and testing new and innovative approaches in the editorial entitled, "Prostate Cancer Gene Therapy: Attempts to Innovate."

Three review articles in the issue explore various aspects of this evolving field and advances that will make it possible to translate new gene therapy techniques from research to testing in human patients. Ellen Schenk and colleagues from Erasmus Medical Center, The Netherlands, and Uppsala University, Sweden, representing the GIANT FP6 Consortium, review current clinical experiences and progress toward the development of adenovirus-mediated gene therapy in the review article entitled, "Clinical Adenoviral Gene Therapy for Prostate Cancer."

Norman Maitland and coauthors from University of York, U.K., Uppsala University, Sweden, and Erasmus Medical Center, The Netherlands, on behalf of the GIANT FP6 Consortium, emphasize the need for laboratory models that more closely mirror human tissues in the article entitled, "Gene Transfer Vectors Targeted to Human Prostate Cancer: Do We Need Better Preclinical Testing Systems?"

Jeroen de Vrij and colleagues from Leiden University Medical Center and Erasmus Medical Center, The Netherlands, and from Got-a-Gene, in Kullavik, Sweden, also representing the GIANT FP6 Consortium, summarize recent advances in adenovirus technology and present state-of-the-art and future prospects for adenoviral vector-based gene therapy in the article entitled, "Adenovirus-Derived Vectors for Prostate Cancer Gene Therapy."

"Achievement of the full potential of gene transfer technologies will depend upon understanding the basic concepts of carcinogenesis in the prostate," says Bernd Gnsbacher, MD, PhD, Deputy Editor of Human Gene Therapy and Director, Institute for Experimental Oncology, Technical University of Munich, Germany.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. NY state the focus of Congressional hearing on how research and innovation fuel local economies
2. ACS Webinar focuses on green chemistry innovations and applications
3. Biotherapeutic Innovations on Display at AAPS National Biotechnology Conference
4. EPA awards more than $1 million to college teams for environmental innovation
5. Research & Entrepreneurship Day 2010: Engineering Innovation
6. Innovation in science
7. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
8. Oberthur Technologies Receives Product Innovation Award
9. Leaders from the National Academies gather to discuss engineering innovations in health care
10. Innovation boost to tackle climate change
11. Innovation puts next-generation solar cells on the horizon
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology: